Biomind Labs Inc. (CVE:BMND.NE) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
Biomind Labs Inc.

BRIEF

published on 12/03/2025 at 14:35, 1 day 15 hours ago

Biomind Labs Advances BMND08 with New Nano-Formulation

Intellectual Property Biomind Labs BMND08 FDA Pathway Nano-formulation
PRESS RELEASE

published on 12/03/2025 at 14:30, 1 day 15 hours ago

Biomind Labs Accelerates FDA Pathway for 5-MEO-DMT Candidate BMND08 with Proprietary Nano-Formulation as Patent Observations Are Successfully Withstood
Biomind Labs advances BMND08 into FDA-directed activities with newly engineered nano-formulation drug-delivery platform, strengthening patent position

FDA Patent Biomind Labs BMND08 Nano-formulation
BRIEF

published on 11/25/2025 at 23:25, 9 days 6 hours ago

Biomind Labs Announces Revocation of Cease Trade Order

Cease Trade Order Financial Challenges Going Concern Biomind Labs Disclosures Filed
PRESS RELEASE

published on 11/25/2025 at 23:20, 9 days 6 hours ago

Biomind Labs Announces Revocation of Cease Trade Order
Biomind Labs Inc. announces the Ontario Securities Commission revokes cease trade order, allowing the filing of Continuous Disclosure Documents. The Company to hold AGSM before February 25, 2026

Cease Trade Order Ontario Securities Commission AGSM Biomind Labs Inc. Continuous Disclosure Documents
BRIEF

published on 11/18/2025 at 23:40, 16 days 6 hours ago

Biomind Labs Files Disclosure and Appoints New Board Member

Cease Trade Order Securities Commission Biomind Labs Disclosure Filing Scott Ackerman
PRESS RELEASE

published on 11/18/2025 at 23:35, 16 days 6 hours ago

Biomind Labs Announces Filing of Continuous Disclosure Documents and Appointment of Scott Ackerman to the Board
Biomind Labs Inc. announces filing of continuous disclosure documents on SEDAR+ including management's discussion & analysis and officer certificates. Company appoints new independent director

Independent Director Ontario Securities Commission SEDAR+ Biomind Labs Inc. Continuous Disclosure Documents
BRIEF

published on 11/21/2024 at 00:30, 1 year ago

Biomind Labs Sees Opportunity in U.S. Policy Shift for Psychedelic Therapies

FDA Approval Psychedelic Therapies Neurological Disorders BMND08 Drug U.S. Policy Shift
PRESS RELEASE

published on 11/21/2024 at 00:25, 1 year ago

Biomind Labs Welcomes U.S. Policy Shift as a Historic Milestone for Psychedelic Therapies
Biomind Labs Inc., a leading biotech company, optimistic about U.S. government's stance on psychedelic industry. Company's BMND08 shows promising results in Phase II trial for neuropsychiatric disorders

FDA Neuropsychiatric Disorders Biomind Labs Inc. BMND08 Psychedelic Industry
BRIEF

published on 07/18/2024 at 14:35, 1 year 4 months ago

Biomind Labs Advances New Obesity Treatment with BMND06 Candidate Targeting Neurological Pathways

Obesity Treatment Clinical Trial Biomind Labs BMND06 Anti-inflammatory
PRESS RELEASE

published on 07/18/2024 at 14:30, 1 year 4 months ago

Biomind Labs To Redefine Obesity Treatment With Its New BMND06 Candidate Targeting Neurological Pathways
Biomind Labs announced the decision to advance a Phase II clinical trial for BMND06, a novel compound with potential anti-inflammatory properties for treating obesity and neurological disorders

Phase II Trial Obesity Biomind Labs BMND06 Anti-inflammatory

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 32 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 37 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 7 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 2 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 7 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 36 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 16 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 41 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 52 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 56 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 7 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 22 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 23 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 6 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE